Journal
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
Volume 30, Issue 2, Pages 441-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.idc.2016.02.007
Keywords
beta- Lactamases; Inhibitor; Diazabicyclooctanones; Boronic acids; Sulfones; Monobactams; Carbapenems; Metallo-beta-lactamases
Categories
Funding
- Cleveland Department of Veterans Affairs
- Veterans Affairs Career Development Program
- Veterans Affairs Merit Review Program Award [1I01BX002872, 1I01BX001974]
- Geriatric Research Education and Clinical Center VISN 10
- Harrington Foundation
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01 AI100560, R01 AI063517]
Ask authors/readers for more resources
Given the serious medical burden of beta-lactamases, many approaches are being used to identify candidate agents for beta-lactamase inhibition. Here, we review two beta-lactam-beta-lactamase inhibitor (BL-BLI) combinations, ceftolozane-tazobactam and ceftazidime-avibactam that recently entered the clinic. In addition, we focus on BL-BLI combinations in preclinical development that have demonstrated activity in clinical isolates via susceptibility testing and/or in in vivo models of infection. We highlight only the BLIs that are able to reduce the Clinical Laboratory Standards Institute (CLSI) breakpoints for the BL partner into the susceptible range. Our analysis includes the primary literature, meeting abstracts, as well as the patent literature.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available